Trials / Completed
CompletedNCT06163001
Role of Exercise in Chronic Liver Disease Patients Undergoing Liver Transplantation
Effects of Supervised Aerobic and Resistance Exercises on Measures of Frailty in Chronic Liver Disease Patients Undergoing Living Donor Liver Transplantation- an Open Label Randomised Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Institute of Liver and Biliary Sciences, India · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this randomised clinical trial (open label) is to test the effect of supervised aerobic and resistance exercises in chronic liver disease patients being planned for living donor liver transplantation (LDLT). The main question it aims to answer are: * If pre-operative supervised aerobic and resistance exercise for 4 weeks can improve the measures of frailty (Liver frailty index, Short physical performance battery, pulmonary function tests) in chronic liver disease patients being planned for LDLT. * Can this approach also translate into clinically significant benefits in the postoperative outcomes of LDLT. Participants will be randomised into two groups receiving either 1. Standard medical therapy along with supervised aerobic and resistance exercises for 4 weeks. 2. Standard medical therapy. The two groups will be compared for progression of the measures of frailty ver the course of their participation as well as their post LDLT outcomes.
Detailed description
1. Aim and Objective - Primary objective: To assess effects of pre-operative aerobic and resistance exercises in decompensated CLD patients planned for LDLT on the measures of frailty after 1 month of supervised exercise. Secondary objectives: To assess effects of pre-operative aerobic and resistance exercises in decompensated CLD patients planned for LDLT on the post LDLT outcomes, myostatin levels (on POD 14) and skeletal muscle mass (on POD14). 2. Methodology: * Study population - Consecutive voluntary adults (\>18 years) with chronic liver disease, planned for living donor liver transplantation fulfilling the conditions as per inclusion and exclusion criteria. * Study design - Interventional study- Open label randomised controlled trial * Study period - From time of ethical clearance till 31st December 2024 * Sample size - Assuming median LFI for CLD patients as 3.9 ± 0.3\*, and assuming an improvement of 5% with introduction of exercise along with SMT after 1 follow up, and keeping alpha of 5%, and power of study as 90%, with 1:1 ratio of cases and controls, then by method of change we need to enroll a total of 54 patients with 27 in each arm. Assuming 10% non compliance, a total of 60 cases will be enrolled, with 30 cases in each arm. * Intervention - Pre-operative supervised exercise-based regimen versus standard medical therapy alone for a minimum duration of 4 weeks. * Monitoring and assessment - Clinical profile of the patient and symptoms will be serially followed during the patients OPD visits. * Adverse effects - Exercise may aggravate encephalopathy, metabolic disorders, AKI/HRS. It may also lead to falls due to cardio-pulmonary intolerance or hepatic encephalopathy. * Stopping rule - Inability to follow the exercise schedule, or development of any of the adverse effects due to exercise as mentioned above. 3. Expected outcome of the project: Better values of measures of frailty and post LDLT outcomes in patients receiving pre-operative concurrent exerises as an intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Supervised aerobic and resistance exercises | 4 weeks of preoperative supervised aerobic and resistance exercises |
| DIETARY_SUPPLEMENT | Dietary supplementation | 4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation |
Timeline
- Start date
- 2023-12-15
- Primary completion
- 2024-12-31
- Completion
- 2025-01-31
- First posted
- 2023-12-08
- Last updated
- 2025-08-24
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT06163001. Inclusion in this directory is not an endorsement.